Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Arrhythmias

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 35 articles:
HTML format



Single Articles


    January 2023
  1. CENTOR RM, Doppalapudi H
    Annals On Call - Atrial Fibrillation: Control Rate or Rhythm?
    Ann Intern Med. 2023 Jan 3:eA220001. doi: 10.7326/A22-0001.
    PubMed    


  2. LADER EW
    In rheumatic heart disease-associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y.
    Ann Intern Med. 2023;176:JC2.
    PubMed     Abstract available


  3. GULATI S, Eckman MH
    Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
    Ann Intern Med. 2023;176:1-9.
    PubMed     Abstract available


    December 2022
  4. MAHESHWARI A, Norby FL, Inciardi RM, Wang W, et al
    Left Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke : A Prospective Cohort Study.
    Ann Intern Med. 2022 Dec 20. doi: 10.7326/M22-1638.
    PubMed     Abstract available


  5. KO D, Benjamin EJ
    Atrial Cardiopathy and Cardioembolic Stroke.
    Ann Intern Med. 2022 Dec 20. doi: 10.7326/M22-3476.
    PubMed    



  6. Correction: Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/L22-0482.
    PubMed    


  7. WEITZ HH, Merli GJ, Siontis K
    Web Exclusive. Annals Consult Guys - Postoperative Atrial Fibrillation.
    Ann Intern Med. 2022;175:CG1.
    PubMed    


    November 2022
  8. HEALEY JS, Krahn AD, Bashir J, Amit G, et al
    Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations : A Randomized, Multicenter Trial.
    Ann Intern Med. 2022 Nov 8. doi: 10.7326/M22-1566.
    PubMed     Abstract available


  9. LAU WCY, Torre CO, Man KKC, Stewart HM, et al
    Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
    Ann Intern Med. 2022 Nov 1. doi: 10.7326/M22-0511.
    PubMed     Abstract available



  10. Correction: Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban and Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2022;175:1627-1628.
    PubMed    


    October 2022
  11. DAWWAS GK, Cuker A, Barnes GD, Lewis JD, et al
    Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study.
    Ann Intern Med. 2022 Oct 18. doi: 10.7326/M22-0318.
    PubMed     Abstract available


    September 2022
  12. KIM D, Yang PS, You SC, Jang E, et al
    Early Rhythm Control Therapy for Atrial Fibrillation in Low-Risk Patients : A Nationwide Propensity Score-Weighted Study.
    Ann Intern Med. 2022 Sep 6. doi: 10.7326/M21-4798.
    PubMed     Abstract available


    August 2022
  13. CHEW DS, Zhou K, Pokorney SD, Matchar DB, et al
    Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis.
    Ann Intern Med. 2022 Aug 16. doi: 10.7326/M21-4653.
    PubMed     Abstract available


  14. KANTHARIA BK
    Left Atrial Appendage Occlusion Versus Anticoagulation in Atrial Fibrillation: Equipoise When Bleeding Risk Is High.
    Ann Intern Med. 2022 Aug 16. doi: 10.7326/M22-2271.
    PubMed    



  15. Summary for Patients: Occlusion Devices Versus Blood Thinners for Atrial Fibrillation.
    Ann Intern Med. 2022 Aug 16. doi: 10.7326/P22-0015.
    PubMed    


    July 2022
  16. SIONTIS KC, Gersh BJ, Weston SA, Jiang R, et al
    Associations of Atrial Fibrillation After Noncardiac Surgery With Stroke, Subsequent Arrhythmia, and Death : A Cohort Study.
    Ann Intern Med. 2022 Jul 26. doi: 10.7326/M22-0434.
    PubMed     Abstract available


  17. ALMHRI A, Leong DP
    In AF, CV benefits of catheter ablation vs. medical therapy may vary by age.
    Ann Intern Med. 2022;175:JC77.
    PubMed     Abstract available


    June 2022
  18. CHOI SE, Lip GYH
    USPSTF found insufficient evidence on the benefits and harms of screening adults >/=50 y for AF.
    Ann Intern Med. 2022;175:JC62.
    PubMed     Abstract available


    February 2022
  19. HUANG HK, Liu PP, Lin SM, Hsu JY, et al
    Diabetes-Related Complications and Mortality in Patients With Atrial Fibrillation Receiving Different Oral Anticoagulants : A Nationwide Analysis.
    Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-3498.
    PubMed     Abstract available


  20. COLIVICCHI F
    In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding.
    Ann Intern Med. 2022;175:JC22.
    PubMed     Abstract available


  21. SANTULLI G, Mone P
    In permanent AF with narrow QRS, AV junction ablation + CRT vs. rate-control drug therapy reduced mortality.
    Ann Intern Med. 2022;175:JC21.
    PubMed     Abstract available


    January 2022
  22. YOUSUFUDDIN M, Jahangir A
    In older patients at high risk for stroke, intensive AF screening with an implantable loop recorder did not reduce stroke.
    Ann Intern Med. 2022;175:JC8.
    PubMed     Abstract available


  23. YOUSUFUDDIN M, Jahangir A
    In adults aged 75 to 76 y, systematic AF screening reduced morbidity and mortality at 6 y.
    Ann Intern Med. 2022;175:JC9.
    PubMed     Abstract available


    December 2021
  24. WILLETT LR, Kim S
    In paroxysmal AF, first-line catheter ablation vs. antiarrhythmic drugs reduces atrial arrhythmia recurrence.
    Ann Intern Med. 2021 Dec 7. doi: 10.7326/ACPJ202112210.
    PubMed     Abstract available


    October 2021
  25. SHAH S, Garg J
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2021;174:1489-1490.
    PubMed    


  26. DAWWAS GK, Barnes GD, Cuker A, Lewis JD, et al
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2021;174:1490.
    PubMed    


  27. RODWIN BA
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2021;174:1488-1489.
    PubMed    


  28. MANSI IA, Bhushan S, Albracht DE
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
    Ann Intern Med. 2021;174:1489.
    PubMed    


    September 2021
  29. SAMPSON C
    In acute atrial flutter, adding pharmacologic before electrical cardioversion did not increase conversion to normal sinus rhythm.
    Ann Intern Med. 2021 Sep 7. doi: 10.7326/ACPJ202109210.
    PubMed     Abstract available


    August 2021
  30. PIANO MR, Hwang CL
    Holiday Heart Confirmed: Alcohol-Associated Atrial Fibrillation.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-3193.
    PubMed    



  31. Summary for Patients: Alcohol Drinking and Atrial Fibrillation.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/P21-0008.
    PubMed    


  32. MARCUS GM, Vittinghoff E, Whitman IR, Joyce S, et al
    Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events.
    Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-0228.
    PubMed     Abstract available


    July 2021
  33. KIM DH, Pawar A, Gagne JJ, Bessette LG, et al
    Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.
    Ann Intern Med. 2021 Jul 20. doi: 10.7326/M20-7141.
    PubMed     Abstract available


    June 2021
  34. KARIMZAD K, Deswal A
    In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo.
    Ann Intern Med. 2021;174:JC69.
    PubMed     Abstract available


    April 2021
  35. GUE YX, Lip GYH
    In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events.
    Ann Intern Med. 2021;174:JC43.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: